These results might help improve our understanding of how the biomarkers FGFR2, VEGF, TRAIL-R1, and TRAIL-R2 relate to recurrence, potentially yielding refinements to clinical staging systems and tumor recurrence predictions through improved stratification of HCC patients having undergone hepatic resection. Here, FGFR2 is linked to hepatocellular carcinoma.